Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF

Launched by UNIVERSITY MEDICAL CENTER GOETTINGEN · Jan 5, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how stiffening of the arteries might predict heart problems, specifically heart failure with preserved ejection fraction (HFpEF). HFpEF is a condition where the heart can pump blood normally but struggles to fill properly, leading to symptoms like shortness of breath and fatigue. The study will involve thorough health assessments, heart ultrasound tests, and pulse-wave analysis to understand the relationship between artery stiffness and heart function.

To participate, you should be over 60 years old and have certain health conditions such as high blood pressure, diabetes, or chronic kidney disease. If you have a body mass index (BMI) of 30 or higher or have specific heart function measurements, you may also qualify. Participants will undergo several tests to assess their heart and overall health. It's important to know that individuals with severe heart issues or certain heart diseases will not be eligible for this trial. If you are interested in learning more or think you might qualify, please reach out to the study team for further details.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• One or more of the following criteria:
• • Age \> 60 years
• • Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)
• • Diabetes mellitus Type I or II
• • Atrial fibrillation
• • Chronic kidney disease (GFR \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g)
• • BMI ≥ 30 kg/m2
• • NYHA ≥ II
• • E/e' \> 8
• Exclusion Criteria:
• • Left ventricular ejection fraction \< 50 %
• • Significant valve disease (Grade III or higher)
• • History of interventional or surgical valve repair
• • Regional wall motion abnormalities
• • Respiratory diseases as a known cause for dyspnea
• • Atrial flutter or fibrillation during examination
• • Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy
• • History of heart transplantation